Abdera Therapeutics Inc. emerged from stealth mode with $142 million in equity funding and plans to develop a pipeline of radiopharmaceutical drugs that will employ engineered heavy-chain-only antibody domains as targeting agents. It has already identified a lead, which targets delta-like ligand 3, a Notch pathway protein, which is overexpressed in about 80% of small-cell lung cancer cases, but which is absent from healthy tissue. A manufacturing campaign is now underway, and an IND submission is in the offing.
Researchers from Memorial Sloan Kettering Cancer Center and affiliated organizations presented data from a study that aimed to investigate the immunomodulatory functions of lysine-specific demethylase 1 (LSD1) in regulating MHC-I antigen presentation pathway (APP) and resistance to immunotherapy in patients with small-cell lung cancer (SCLC).
Shanghai Henlius Biotech Inc. scored NMPA approval for its self-developed anti-PD-1 monoclonal antibody Hansizhuang (serplulimab). It can be used for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide.
Major histocompatibility complex class I (MHC-I) gene promoters are bivalently modified during development, which can be exploited in cancer cells to silence MHC-I expression and evade CD8+ T cells; in cells that exhibit bivalent modification of MHC-I genes, lower levels of cell surface MHC-I can be induced either by PRC2 inhibition or exposing the cells to interferon γ (IFNγ) in conjunction with polycomb inhibition to allow a permissive chromatin status.
Cofactor Genomics Inc. opened the non-small-cell lung cancer portion of its study of the Oncoprism test, which predicts response to immunotherapy. The Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies (PREDAPT) trial will study the test’s predictive ability in 11 cancers in total.
Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharmaceutical Tech Co. Ltd. have divulged new polycyclic lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of small-cell lung cancer (SCLC).
Medshine Discovery Inc. has identified thiophene compounds acting as lysine-specific histone demethylase 1A (LSD1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Henlius Biotech Inc.’s anti-PD-1 monoclonal antibody serplulimab has generated positive data in a phase III trial as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC).
